April 11, 2014
Keiji Nakamura, Ph.D. Pharma Forum Institute Lambrolizumab (MK-3475) of Merck & Co. MK-3475 is also a humanized IgG4 mab against PD-1, especially effective for melanoma, as designated as a breakthrough therapy by the FDA in 2013 and its second cancer...read more